Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

Thitima Kongnakorn,1 James A Sterchele,2 Christopher G Salvador,3 Denis Getsios,4 Mkaya Mwamburi51Evidera, Bangkok, Thailand; 2formerly of Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA, 3Oncology Market Research, Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA,...

Full description

Bibliographic Details
Main Authors:	Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-04-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/economic-implications-of-using-bendamustine-alemtuzumab-or-chlorambuci-a16296

Similar Items

Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase IIIb Study (MaBLe).
by: Leblond, V, et al.
Published: (2012)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
by: Francesco Autore, et al.
Published: (2020-06-01)

Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

The expanding role of bendamustine in chronic lymphocytic leukemia
by: Nair KS, et al.
Published: (2015-07-01)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
by: Casado LF, et al.
Published: (2016-09-01)

Bendamustine: a new view on treatment of chronic lymphocytic leukemia
by: Ye. A. Nikitin
Published: (2022-11-01)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
by: Sara E. F. Kost, et al.
Published: (2019-10-01)

Acute Myeloid Leukemia Secondary to Chronic Lymphocytic Leukemia After Prolonged Chlorambucil Therapy: A Case Report
by: Wu Y, et al.
Published: (2023-04-01)

IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01)

Efficacy of combination of rituximab therapy with chlorambucil plus prednisolone (R-LP) Protocol as treatment line in chronic lymphocytic leukemia patients
by: Waseem F Al Tameemi
Published: (2015-01-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008-03-01)

Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study
by: E A Stadnik, et al.
Published: (2017-07-01)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
by: Steven E. Coutre, et al.
Published: (2018-06-01)

Bendamustine and Rituximab Treatment, Chronic Lymphocytic Leukemia, Direct Antiglobulin Test, and False Negatives
by: Won Sriwijitalai, et al.
Published: (2019-02-01)

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia
by: Nicole Bourrier, et al.
Published: (2022-02-01)

Chlorambucil and fludarabine as a new pre-transplant conditioning for patients with chronic lymphocytic leukemia: results of in vivo experiments
by: J. Tomenendalova, et al.
Published: (2008-10-01)

Case Report: Long-Term Survival of a Dog With Chronic Lymphocytic Leukemia Treated With Chlorambucil, Prednisolone, and Imatinib
by: Ga-Won Lee, et al.
Published: (2022-01-01)

Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
by: Martina Bogeljić Patekar, et al.
Published: (2018-01-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Azathioprine, cyclophosphamide and chlorambucil.
by: Luqmani, R, et al.
Published: (1990)

Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases
by: Rafet Eren, et al.
Published: (2018-11-01)

Honokiol-Chlorambucil Co-Prodrugs Selectively Enhance the Killing Effect through STAT3 Binding on Lymphocytic Leukemia Cells In Vitro and In Vivo
by: Li Xia, et al.
Published: (2020-07-01)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
by: Hale, G, et al.
Published: (2004)

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
by: Hillmen, P, et al.
Published: (2014)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
by: Shinya Rai, et al.
Published: (2018-09-01)

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN
by: J. P. Sharman, et al.
Published: (2022-06-01)

Chlorambucil-iron oxide nanoparticles as a drug delivery system for leukemia cancer cells
by: Al-Ali, Samer Hasan Hussein, et al.
Published: (2021)

Potent Chlorambucil-Platinum(IV) Prodrugs
by: Angelico D. Aputen, et al.
Published: (2022-09-01)

HPLC-UV and GC-MS Methods for Determination of Chlorambucil and Valproic Acid in Plasma for Further Exploring a New Combined Therapy of Chronic Lymphocytic Leukemia
by: Katarzyna Lipska, et al.
Published: (2021-05-01)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
by: Antonio Cuneo, et al.
Published: (2020-11-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
by: Lundin, J, et al.
Published: (2001)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-04-01)

Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
by: James E, et al.
Published: (2021-03-01)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
by: Jan J. Meeuse, et al.
Published: (2007-12-01)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
by: Andrea Visentin, et al.
Published: (2022-11-01)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
by: Havrdova E, et al.
Published: (2017-10-01)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
by: Othman Al-Sawaf, et al.
Published: (2023-10-01)